Table 2.
Treatment compliance by treatment group
| RFA plus systemic treatment (N = 60) | Systemic treatment (N = 59) | |
|---|---|---|
| Treatment received | N (%) | N (%) |
| Folfox | 43 (71.7) | 46 (78.0) |
| Folfox + bevacizumab | 8 (13.3) | 13 (22.0) |
| RFA only | 6 (10.0) | |
| No treatment | 3 (5.0) | |
| Administration of chemotherapy | ||
| No. of cycles | N (%) | N (%) |
| 0 | 9 (15.0) | 0 (0.0) |
| 1–4 | 14 (23.3) | 15 (25.4) |
| 5–8 | 7 (11.7) | 4 (6.8) |
| 9–11 | 8 (13.3) | 13 (22.0) |
| 12 | 22 (36.7) | 27 (45.8) |
| Median | 8.5 | 10.0 |
| RDI (%) | Median (range) | Median (range) |
| RDI 5-FU (N = 110) | 83 (49–105) | 91 (50–104) |
| RDI folinic acid (N = 109) | 92 (46–200) | 95 (51–200) |
| RDI oxaliplatin (N = 110) | 80 (18–101) | 83 (37–103) |
| RDI bevacizumab (N = 21) | 94 (34–102) | 97 (13–101) |
RDI, relative dose intensity; RFA, radiofrequency ablation.